Patents by Inventor James Barnaby Trager

James Barnaby Trager has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12351617
    Abstract: Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: July 8, 2025
    Assignees: National University of Singapore, Nkarta, Inc.
    Inventors: Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
  • Publication number: 20250073266
    Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express cytotoxic chimeric receptors and various dosing regimens for administering such cells. In several embodiments, the immune cells express a chimeric receptor that targets ligands of NKG2D on tumor cells. In several embodiments, the cancer is a blood cancer, for example, acute myeloid leukemia (e.g., relapsed/refractory acute myeloid leukemia) or myelodysplastic syndrome. In several embodiments, the tumor is a solid tumor, for example, intrahepatic cholangiocarcinoma or other liver tumor, for example, secondary metastases from colorectal cancer.
    Type: Application
    Filed: May 11, 2022
    Publication date: March 6, 2025
    Inventors: Kanya Lakshmi Rajangam, Minoti Murughesh Hiremath, James Barnaby Trager, David Richard Shook, Aaron Norvin Endsley
  • Publication number: 20240360234
    Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.
    Type: Application
    Filed: May 7, 2024
    Publication date: October 31, 2024
    Inventors: James Barnaby Trager, Alexandra Leida Liana Lazetic, Ivan Chan, Chao Guo, Katherine Jamboretz
  • Publication number: 20240358758
    Abstract: Provided herein are methods of treating subjects having or suspected of having an autoimmune disease (e.g., systemic lupus erythematosus and/or lupus nephritis) with natural killer (NK) cells, and related compositions, uses, and articles of manufacture. In some aspects, the NK cells express a recombinant receptor, such as a CD19-directed chimeric antigen receptor (CAR).
    Type: Application
    Filed: April 4, 2024
    Publication date: October 31, 2024
    Inventors: David Richard Shook, James Barnaby Trager, Nishi Kothari, Alison Blaus, Phung Gip, Alexandra Leida Liana Lazetic, Sandeep Hora, Wendy Yu, Meriam Vejiga, Mira Tohmé
  • Publication number: 20240335536
    Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to Mexpress chimeric antigen receptors as well as genetically edited or otherwise engineered to alter the effectiveness with which another immune cell can target and induce cytotoxic effects on the engineered cells. In several embodiments, the methods and compositions disclosed herein reduce fratricide within a therapeutic cell population, which in some instances comprises mixture of immune cell types. Additionally, the methods and compositions disclosed herein enhance one or more aspects of the efficacy of the immune cells in cellular immunotherapy including cytotoxicity and/or persistence, as well as reduced graft versus host or host versus graft effects.
    Type: Application
    Filed: December 2, 2021
    Publication date: October 10, 2024
    Inventors: James Barnaby Trager, Ivan Chan, Don-Hong Wang, Guangnan Li, Alexandra Leida Liana Lazetic, Chao Guo
  • Patent number: 12012458
    Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: June 18, 2024
    Assignee: NKARTA, INC.
    Inventors: James Barnaby Trager, Alexandra Leida Liana Lazetic, Ivan Chan, Chao Guo, Katherine Jamboretz
  • Publication number: 20230390392
    Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a combination of genes and their corresponding proteins. In several embodiments, one edit is to reduce expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR and at least two additional gene edits to enhance the cytotoxicity and/or persistence of the resulting cells. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.
    Type: Application
    Filed: March 6, 2023
    Publication date: December 7, 2023
    Inventors: James Barnaby Trager, Ivan Chan, Chao Guo, Luxuan Guo Buren, Alexandra Leida Liana Lazetic, Mary-Lee Dequéant, Hanspeter Waldner, Changan Guo, Chandirasegaran Massilamany, Ming-Hong Xie, Elizabeth N. Koch, Jacob Usadi, Parin Sripakdeevong
  • Publication number: 20230265390
    Abstract: Several embodiments disclosed herein relate to methods and compositions for enhanced expansion of NK cells in culture. In several embodiments, the methods utilize one or more soluble interleukins as culture media supplements at one or more time points during expansion of the NK cell, or other immune cell, the expansion employing a feeder cell population.
    Type: Application
    Filed: August 31, 2021
    Publication date: August 24, 2023
    Inventors: James Barnaby Trager, Alexandra Leida Liana Lazetic, Katherine Jamboretz, Muhammad Nafeesur Rahman
  • Publication number: 20230028399
    Abstract: Provided for herein in several embodiments are immune cell-based compositions comprising BCMA-directed chimeric antigen receptors (CAR). In several embodiments, the immune-cell based compositions also target an additional tumor marker and/or an additional epitope of BCMA. In several embodiments, the BCMA-directed CAR is expressed in a Natural Killer cell. In several embodiments, combinations of BCMA-CAR-expressing NK cells are administered in conjunction with, for example CAR-expressing NK cells and/or CAR-expressing T cells that are directed to an additional cancer marker and/or an additional epitope of BCMA. Also provided for herein are methods and uses of the chimeric antigen receptors in immunotherapy.
    Type: Application
    Filed: January 11, 2021
    Publication date: January 26, 2023
    Inventors: Kanya Lakshmi Rajangam, James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Alexandra Leida Liana Lazetic
  • Publication number: 20230002471
    Abstract: Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.
    Type: Application
    Filed: May 10, 2022
    Publication date: January 5, 2023
    Inventors: Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
  • Publication number: 20220411754
    Abstract: Several embodiments disclosed herein relate to methods and compositions for enhanced expansion of NK cells in culture. In several embodiments, the methods utilize one or more soluble interleukins as culture media supplements at one or more time points during expansion of the NK cell, or other immune cell, the expansion employing a feeder cell population.
    Type: Application
    Filed: July 29, 2020
    Publication date: December 29, 2022
    Inventors: James Barnaby TRAGER, Alexandra Leida Liana LAZETIC, Ivan CHAN, Anmol VOHRA
  • Publication number: 20220233593
    Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors and/or genetically modified to enhance one or more aspects of the efficacy of the immune cells in cellular immunotherapy. Several embodiments relate to genetic modifications which reduce potential side effects of cellular immunotherapy. In several embodiments, combinations of cells are used to achieve both rapid and long-term tumor reduction with reduced or eliminated potential for graft versus host effects.
    Type: Application
    Filed: June 2, 2020
    Publication date: July 28, 2022
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Guangnan Li, Daofeng Liu, Ivan Chan
  • Publication number: 20220233590
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Application
    Filed: January 7, 2022
    Publication date: July 28, 2022
    Inventors: James Barnaby TRAGER, Luxuan Guo BUREN, Chao GUO, Mira TOHMÉ, Ivan CHAN, Alexandra Leida Liana LAZETIC
  • Patent number: 11365236
    Abstract: Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: June 21, 2022
    Assignees: NKARTA, INC., NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
  • Patent number: 11253547
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: February 22, 2022
    Assignee: Nkarta, Inc.
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
  • Publication number: 20220002424
    Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.
    Type: Application
    Filed: June 10, 2021
    Publication date: January 6, 2022
    Inventors: James Barnaby Trager, Alexandra Leida Liana Lazetic, Ivan Chan, Chao Guo, Katherine Jamboretz
  • Publication number: 20210338727
    Abstract: Several embodiments disclosed herein relate to the treatment of a tumor using immunotherapy. Several embodiments relate to the treatment of a liver tumor, such as hepatocellular carcinoma or a metastasis from another tumor location. Additional embodiments relate to combination therapies that employ Natural Killer (NK) cells engineered to express cytotoxic receptor complexes and additional anti-cancer agents to treat tumors.
    Type: Application
    Filed: September 11, 2019
    Publication date: November 4, 2021
    Inventors: James Barnaby TRAGER, Angela Jean SHEN
  • Patent number: 11154575
    Abstract: Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy. Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: October 26, 2021
    Assignee: Nkarta, Inc.
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
  • Patent number: 11141436
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: October 12, 2021
    Assignee: Nkarta, Inc.
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
  • Publication number: 20210070857
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 11, 2021
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic